OPTN Earnings Prediction
The chart below shows how OPTN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, OPTN sees a -1.96% change in stock price 10 days leading up to the earnings, and a -7.84% change 10 days following the report. On the earnings day itself, the stock moves by -2.55%. This data can give you a slight idea of what to expect for the next quarter's release.
OPTN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
20.44M
3.10%
-0.26%
Gross Margin
89.90%
1.26%
-0.48%
Operating Margin
-10.04%
17.43%
-68.59%
Net Margin
2.29%
104.88%
-106.19%
EPS
0.00
-100.00%
-100.00%
No Data Available
OPTN Earnings Analysis
OptiNose, Inc. Common Stock Corporation (OPTN.O) Earnings Conference Call
Positive
XHANCE Revenue Increase: OptiNose recognized $20.4 million of XHANCE net revenue in the third quarter of 2024, a 3% increase compared to third quarter 2023 net revenues of $19.8 million.
Quarterly Revenue Increase: Revenue in the quarter reflects an increase in inventory in the channel, driven in part by the addition of new dispensing pharmacies in the hub pharmacy network.
Prescription Revenue Increase: The estimated XHANCE average net revenue per prescription for the third quarter of 2024 was $320, a 36% increase compared to $236 of estimated average net revenue per prescription in the third quarter of 2023.
Business Mix Improvement: The year-over-year increase is driven by favorable business mix resulting from the changes we made to our co-pay support program, which improved our commercial business mix and by the channel inventory build associated in part with the onboarding of new pharmacies in the latter part of the third quarter.
XHANCE Revenue Increase: OptiNose recognized $55.8 million of XHANCE net revenue year-to-date through September 2024, a 9% increase compared to prior year period XHANCE net revenue of $51.1 million.
Negative
Third Quarter Revenue Impact: Revenue in the third quarter was affected by some inventory stocking in the channel, driven in part by the addition of new dispensing pharmacies in the hub pharmacy network, resulting in a net revenue of $20.4 million, which is less than expected.
Operating Expenses Increase: Operating expenses recognized in the third quarter of 2024 increased to approximately $20.4 million, reflecting a 3% increase compared to the previous year, which may indicate rising costs.
Revenue Guidance Adjustment: The expected full-year guidance for XHANCE net revenue has been adjusted down to between $75 million and $79 million, compared to previous expectations of $85 million to $90 million.
Net Revenue Per Prescription Growth: The average net revenue per prescription for the third quarter was $320, a 36% increase compared to $236 from the previous year, but still indicates a need for improvement in sales execution.
SG&A and R&D Expenses Increase: The company recognized $67.2 million in SG&A plus R&D expenses year-to-date through September 2024, which is an increase of approximately $2 million compared to the previous year.
OPTN FAQs
How does OPTN typically perform around its earnings report dates?
Is OptiNose, Inc. (OPTN) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
OPTN Earning Call Sentiment
OptiNose, Inc. (OPTN) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
OPTN.O
-0.56%Positive
The earnings call highlighted several concerns: conservative revenue guidance, challenges with insurance coverage, and unclear management responses in the Q&A. Financial performance showed modest growth, but guidance was lowered, and no shareholder returns were announced. Despite positive revenue per prescription, the lack of concrete guidance and competitive pressures in the market suggest a negative sentiment. These factors, combined with economic uncertainties and the absence of a market cap, lead to a prediction of a stock price decrease in the range of -2% to -8% over the next two weeks.
